Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab vs Triamcinolone for Acute Gouty Arthritis Flares
NCT01356602Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of canakinumab in acute gouty arthritis, sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT01356602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356602.